Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Lbp Am Sa

Lbp Am Sa decreased its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 15.8% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 25,133 shares of the company’s stock after selling 4,733 shares during the quarter. Lbp Am Sa’s holdings in Neurocrine Biosciences were worth $3,431,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Caprock Group LLC acquired a new stake in shares of Neurocrine Biosciences during the fourth quarter worth about $236,000. Charles Schwab Investment Management Inc. lifted its position in Neurocrine Biosciences by 2.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 762,557 shares of the company’s stock valued at $104,089,000 after purchasing an additional 15,266 shares during the period. Swiss National Bank lifted its position in Neurocrine Biosciences by 1.4% in the third quarter. Swiss National Bank now owns 298,700 shares of the company’s stock valued at $34,416,000 after purchasing an additional 4,100 shares during the period. Tri Ri Asset Management Corp acquired a new stake in Neurocrine Biosciences in the third quarter valued at about $3,236,000. Finally, KBC Group NV lifted its position in Neurocrine Biosciences by 78.3% in the third quarter. KBC Group NV now owns 18,972 shares of the company’s stock valued at $2,186,000 after purchasing an additional 8,332 shares during the period. Institutional investors and hedge funds own 92.59% of the company’s stock.

Insider Activity

In other news, insider Julie Cooke sold 1,740 shares of the business’s stock in a transaction on Friday, January 31st. The shares were sold at an average price of $152.89, for a total transaction of $266,028.60. Following the completion of the sale, the insider now directly owns 18,202 shares of the company’s stock, valued at $2,782,903.78. The trade was a 8.73 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Ingrid Delaet sold 272 shares of the business’s stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $138.10, for a total transaction of $37,563.20. Following the sale, the insider now directly owns 2,507 shares of the company’s stock, valued at $346,216.70. This represents a 9.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 234,269 shares of company stock valued at $34,053,879 in the last ninety days. Company insiders own 4.30% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the stock. UBS Group raised their price objective on shares of Neurocrine Biosciences from $162.00 to $176.00 and gave the company a “buy” rating in a research report on Thursday, January 30th. Wedbush reduced their price objective on shares of Neurocrine Biosciences from $157.00 to $147.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. Canaccord Genuity Group reduced their price objective on shares of Neurocrine Biosciences from $172.00 to $163.00 and set a “buy” rating for the company in a research report on Friday, February 7th. Royal Bank of Canada reduced their price target on shares of Neurocrine Biosciences from $154.00 to $148.00 and set a “sector perform” rating for the company in a research report on Friday, February 7th. Finally, Piper Sandler reiterated an “overweight” rating and set a $160.00 price target on shares of Neurocrine Biosciences in a research report on Monday, December 23rd. Five research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $165.24.

Neurocrine Biosciences Stock Performance

NBIX stock opened at $110.75 on Friday. The stock has a market capitalization of $11.04 billion, a P/E ratio of 33.66, a PEG ratio of 0.77 and a beta of 0.35. Neurocrine Biosciences, Inc. has a one year low of $105.18 and a one year high of $157.98. The company has a 50 day moving average price of $129.69 and a two-hundred day moving average price of $125.69.

Neurocrine Biosciences (NASDAQ:NBIX) last released its earnings results on Thursday, February 6th. The company reported $1.00 EPS for the quarter, missing the consensus estimate of $1.62 by ($0.62). Neurocrine Biosciences had a return on equity of 13.38% and a net margin of 14.49%. Research analysts forecast that Neurocrine Biosciences, Inc. will post 4.28 earnings per share for the current fiscal year.

Neurocrine Biosciences announced that its Board of Directors has initiated a stock buyback plan on Friday, February 21st that authorizes the company to buyback $500.00 million in shares. This buyback authorization authorizes the company to purchase up to 4.2% of its shares through open market purchases. Shares buyback plans are often a sign that the company’s leadership believes its shares are undervalued.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.